Entera Bio Ltd. (NASDAQ:ENTX – Get Rating) was the target of a large increase in short interest in the month of March. As of March 31st, there was short interest totalling 228,200 shares, an increase of 22.8% from the March 15th total of 185,900 shares. Currently, 1.0% of the shares of the company are short sold. Based on an average daily volume of 228,500 shares, the short-interest ratio is currently 1.0 days.

Insiders Place Their Bets

In other Entera Bio news, CEO Miranda Jayne Toledano bought 30,000 shares of Entera Bio stock in a transaction dated Tuesday, April 4th. The shares were purchased at an average cost of $1.01 per share, for a total transaction of $30,300.00. Following the acquisition, the chief executive officer now directly owns 86,800 shares in the company, valued at approximately $87,668. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. 5.15% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. PNC Financial Services Group Inc. acquired a new stake in Entera Bio during the 1st quarter worth $29,000. Millennium Management LLC raised its position in Entera Bio by 358.5% during the 4th quarter. Millennium Management LLC now owns 46,000 shares of the company's stock worth $34,000 after buying an additional 35,968 shares during the last quarter. Finally, Renaissance Technologies LLC raised its position in Entera Bio by 555.4% during the 4th quarter. Renaissance Technologies LLC now owns 139,600 shares of the company's stock worth $102,000 after buying an additional 118,300 shares during the last quarter. Institutional investors and hedge funds own 20.12% of the company's stock.

Entera Bio Stock Performance

Shares of Entera Bio stock traded down $0.02 on Thursday, reaching $0.85. The company had a trading volume of 27,324 shares, compared to its average volume of 212,370. Entera Bio has a 52-week low of $0.47 and a 52-week high of $2.95. The firm's 50 day moving average price is $1.00 and its two-hundred day moving average price is $0.86. The firm has a market cap of $24.48 million, a PE ratio of -1.89 and a beta of 1.83.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a "buy" rating and issued a $10.00 price objective on shares of Entera Bio in a research note on Tuesday, April 4th.

Entera Bio Company Profile

(Get Rating)

Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of orally delivered large molecule therapeutics. It s pipeline include PTH, GLP-E, and hGh, The company was founded on September 30, 2009 and is headquartered in Jerusalem, Israel.

Featured Articles

• Get a free copy of the StockNews.com research report on Entera Bio (ENTX)
• Finding New Technology to Invest in: A Guide
• Genuine Parts Company Is Genuinely A Good Buy
• Healthcare Sector: Overview and Keys to Investing
• Can D.R. Horton Shares Raise The Roof, Or Is This The Ceiling?
• American Express Growth Riding On Joyful Consumer Spending

Receive News & Ratings for Entera Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entera Bio and related companies with MarketBeat.com's FREE daily email newsletter.